^
Association details:
Biomarker:VTCN1 overexpression
Cancer:Bladder Cancer
Drug Class:PD-L1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer

Published date:
06/16/2022
Excerpt:
MIBC patients with the high level of B7-H4 expression (B7-H4high) were found to possess an inferior overall and recurrence-free survival. Nonetheless, substantial clinical benefits of cisplatin-based chemotherapy and anti-PD-L1 immunotherapy were observed in these patients....Despite adverse clinical outcomes, B7-H4high patients possessed superior responsiveness to chemotherapy and immunotherapy.
DOI:
10.1016/j.ejca.2022.05.022